PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 10859312-3 2000 PTPepsilonC expression resulted in lower levels of IL-6-induced tyrosine phosphorylation of Jak1, Tyk2, gp130, and Stat3 compared with parent cells. Tyrosine 64-72 Janus kinase 1 Mus musculus 92-96 10438942-6 1999 Tyrosine phosphorylation of JAK1, JAK2, and IFN-gamma R alpha was also reduced in infected cells. Tyrosine 0-8 Janus kinase 1 Mus musculus 28-32 10666420-5 2000 Indeed, in R3T3 cells, IFN-gamma treatment resulted in rapid activation of Janus kinase (Jak) 1, Jak2, and STAT1 via tyrosine phosphorylation. Tyrosine 117-125 Janus kinase 1 Mus musculus 75-95 9202205-6 1997 The protein levels and the tyrosine phosphorylation of JAK1, JAK2, and STAT3 in F9 cells were not different from those in dF9 cells. Tyrosine 27-35 Janus kinase 1 Mus musculus 55-59 10421786-3 1999 However, disruption of a membrane-proximal proline-rich sequence motif ("box1") in either subunit of the bipartite IL-4R abolished not only ligand-induced tyrosine phosphorylation of Janus kinases JAK1 and JAK3, but also IL-4-triggered activation of STAT5 and concomitant cell proliferation. Proline 43-50 Janus kinase 1 Mus musculus 197-201 9510175-3 1998 In this study, we show that murine TNF induces the tyrosine phosphorylation and activation of the intracellular Janus tyrosine kinases Jak1, Jak2, and Tyk2 in murine 3T3-L1 adipocytes. Tyrosine 51-59 Janus kinase 1 Mus musculus 135-139 9343427-10 1997 SH2-Bbeta was also tyrosyl phosphorylated in response to gamma interferon, a cytokine that activates JAK2 and JAK1. cyclo(tyrosyl-tyrosyl) 19-26 Janus kinase 1 Mus musculus 110-114 9238016-3 1997 We show that Jaks are activated by tyrosine phosphorylation in cells that are briefly exposed to the PTP inhibitor pervanadate (PV), resulting in tyrosine phosphorylation and functional activation of Stat6 (in addition to other Stats). Tyrosine 35-43 Janus kinase 1 Mus musculus 13-17 9238016-3 1997 We show that Jaks are activated by tyrosine phosphorylation in cells that are briefly exposed to the PTP inhibitor pervanadate (PV), resulting in tyrosine phosphorylation and functional activation of Stat6 (in addition to other Stats). pervanadate 115-126 Janus kinase 1 Mus musculus 13-17 9238016-3 1997 We show that Jaks are activated by tyrosine phosphorylation in cells that are briefly exposed to the PTP inhibitor pervanadate (PV), resulting in tyrosine phosphorylation and functional activation of Stat6 (in addition to other Stats). pervanadate 128-130 Janus kinase 1 Mus musculus 13-17 9238016-3 1997 We show that Jaks are activated by tyrosine phosphorylation in cells that are briefly exposed to the PTP inhibitor pervanadate (PV), resulting in tyrosine phosphorylation and functional activation of Stat6 (in addition to other Stats). Tyrosine 146-154 Janus kinase 1 Mus musculus 13-17 9488432-4 1998 While the Janus protein tyrosine kinase JAK2 and the transcription factor STAT5 became tyrosine phosphorylated with the EPO stimulation in EPO-responsive erythroblastoid cells from anemic mice, JAK1 and STAT5 were constitutively tyrosine phosphorylated in all of these FVp gp55-induced erythroblastoid or erythroleukemic cells. Tyrosine 24-32 Janus kinase 1 Mus musculus 194-198 9006890-7 1997 In anti-JAK1 immunoprecipitates from v-Src-transformed NIH3T3 cells, a protein with the same migration as JAK1 showed substantially increased levels of 32P incorporation compared to immunoprecipitates from non-transformed cells. Phosphorus-32 152-155 Janus kinase 1 Mus musculus 106-110 9218758-7 1997 We found that TGF-beta inhibited tyrosine phosphorylation of JAK1, JAK3, STAT3 and STAT5 in Con A blasts from NOD splenocytes and HT-2 cells. Tyrosine 33-41 Janus kinase 1 Mus musculus 61-65 9006890-4 1997 In three v-Src-transformed fibroblast cell lines (NIH3T3, Balb/c, and 3Y1), JAK1 displayed increased tyrosyl phosphorylation compared to non-transformed cells. cyclo(tyrosyl-tyrosyl) 101-108 Janus kinase 1 Mus musculus 76-80 9006890-5 1997 The level of tyrosyl phosphorylation of JAK1 was significantly greater in NIH3T3 cells transformed by expression of v-Src or high levels of a constitutively active mutant of c-Src (Y527F) than in cells overexpressing the less transforming normal c-Src. cyclo(tyrosyl-tyrosyl) 13-20 Janus kinase 1 Mus musculus 40-44 9006890-7 1997 In anti-JAK1 immunoprecipitates from v-Src-transformed NIH3T3 cells, a protein with the same migration as JAK1 showed substantially increased levels of 32P incorporation compared to immunoprecipitates from non-transformed cells. Phosphorus-32 152-155 Janus kinase 1 Mus musculus 8-12 9006890-8 1997 Similar results were obtained using anti-JAK2 immunoprecipitates; however, the level of JAK2 tyrosyl phosphorylation and 32P incorporation in anti-JAK2 immunoprecipitates were markedly lower than in anti-JAK1 immunoprecipitates. cyclo(tyrosyl-tyrosyl) 93-100 Janus kinase 1 Mus musculus 204-208 7489741-2 1995 IL-7 was observed to induce a rapid and dose-dependent tyrosine phosphorylation of Jak 1 and Jak 3 and concomitantly, the tyrosine phosphorylation and DNA binding activity of multiple STAT proteins. Tyrosine 55-63 Janus kinase 1 Mus musculus 83-88 8703030-10 1996 In addition to Stat6, Stat5a, and Stat5b, PDGF BB also induced Jak1 tyrosine phosphorylation suggesting a potential pathway for Stat activation. Tyrosine 68-76 Janus kinase 1 Mus musculus 63-67 8657151-6 1996 Here, we show that all three of the ubiquitously expressed JAKs--JAK1, JAK2, and Tyk2--become phosphorylated on tyrosine in both mouse BALB/c 3T3 cells and human fibroblasts engineered to express the PDGF-beta receptor. Tyrosine 112-120 Janus kinase 1 Mus musculus 59-63 8657151-6 1996 Here, we show that all three of the ubiquitously expressed JAKs--JAK1, JAK2, and Tyk2--become phosphorylated on tyrosine in both mouse BALB/c 3T3 cells and human fibroblasts engineered to express the PDGF-beta receptor. Tyrosine 112-120 Janus kinase 1 Mus musculus 65-69 7544437-7 1995 In cells expressing both wild-type and mutant IL-10R, stimulation with IL-10 leads to tyrosine phosphorylation of the kinases JAK1 and TYK2 but not JAK2 or JAK3 under the conditions tested. Tyrosine 86-94 Janus kinase 1 Mus musculus 126-130 7544789-5 1995 Cotransfection studies and in vitro experiments directly demonstrate that JAK1, JAK2, or JAK3 is capable of tyrosine phosphorylating IRS-1, suggesting a functional role for these kinases in vivo. Tyrosine 108-116 Janus kinase 1 Mus musculus 74-78 7637029-1 1995 Treatment of murine Friend cells with a dose of the protein kinase inhibitor staurosporine, which is able to block the response of the cells to interferons, appears to inhibit phosphorylation of Jak proteins and, interestingly, to specifically reduce tyk2 and Jak1 expression and to increase Jak2 both in the presence and in the absence of interferons. Staurosporine 77-90 Janus kinase 1 Mus musculus 260-264 33811972-8 2021 In addition, blocking JAK-STAT signaling using ruxolitinib reduced the activation of STAT1 in stimulated immune effector cells. ruxolitinib 47-58 Janus kinase 1 Mus musculus 22-25 8007943-8 1994 In particular, cotransfection of expression constructs for Stat4 and Jak1 and Jak2 results in the tyrosine phosphorylation of Stat4 and the acquisition of the ability to bind to the gamma interferon (IFN-gamma)-activated sequence of the interferon regulatory factor 1 (IRF-1) gene. Tyrosine 98-106 Janus kinase 1 Mus musculus 69-73 8013458-9 1994 However, only in BAF-3 cells expressing the PRL-R does PRL induce rapid and transient tyrosine phosphorylation of JAK1. Tyrosine 86-94 Janus kinase 1 Mus musculus 114-118 8134389-3 1994 JAK1 is also tyrosine phosphorylated, but to a lesser extent, under the same conditions. Tyrosine 13-21 Janus kinase 1 Mus musculus 0-4 33811972-0 2021 Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease. ruxolitinib 47-58 Janus kinase 1 Mus musculus 26-32 33811972-1 2021 The objective of this study was to examine the therapeutic effect of ruxolitinib, an orally administered selective Janus Kinase (JAK) 1/2 inhibitor, on chronic graft-versus-host disease (cGVHD) using a murine model of sclerodermatous GVHD (scl-GVHD). ruxolitinib 69-80 Janus kinase 1 Mus musculus 115-137 33811972-9 2021 Taken together, these results suggest that ruxolitinib can prevent scl-GVHD by suppressing IFN-gamma produced by T cells and MCP-1 expression in macrophage/monocytes via inhibition of JAK-STAT signaling. ruxolitinib 43-54 Janus kinase 1 Mus musculus 184-187 34896967-10 2022 Here inhibition mechanism of 6-gingerol is demonstrated on excessive hypertrophy and hyperplasia of adipocytes in white adipose tissue (WAT), which may be related to the regulation of adipocytokines, such as PPARgamma, C/EBPalpha, FABP4 and adiponectin, and the TLR3/IL-6/JAK1/STAT3 axis. gingerol 29-39 Janus kinase 1 Mus musculus 272-276 33589712-1 2021 Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. ruxolitinib 0-11 Janus kinase 1 Mus musculus 25-39 33589712-1 2021 Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. ruxolitinib 0-11 Janus kinase 1 Mus musculus 41-45 34730109-7 2021 Mechanistic studies using the JAK1/2 inhibitor baricitinib revealed marked impairment of T and NK cell survival, proliferation and effector function. baricitinib 47-58 Janus kinase 1 Mus musculus 30-36 34919889-1 2022 Tofacitinib is the first selective Janus kinase (JAK) 1/3 inhibitor approved for the treatment of rheumatoid arthritis and has been demonstrated to exhibit its efficacy through suppression of lymphocyte activation. tofacitinib 0-11 Janus kinase 1 Mus musculus 35-57 34747340-0 2021 MiR-125-5p/IL-6R axis regulates macrophage inflammatory response and intestinal epithelial cell apoptosis in ulcerative colitis through JAK1/STAT3 and NF-kappaB pathway. mir-125- 0-8 Janus kinase 1 Mus musculus 136-140 34747340-12 2021 In addition, miR-125-5p up-regulation significantly reduced the expression of IL-6 R in the UC mice, and reduced the expression levels of JAK1, STAT3 and p65 phosphorylation. mir-125-5p 13-23 Janus kinase 1 Mus musculus 138-142 34747340-13 2021 MiR-125-5p targeting IL-6 R regulates macrophage inflammatory response and intestinal epithelial cell apoptosis in ulcerative colitis through JAK1/STAT3 and NF-kappaB pathway. mir-125-5p 0-10 Janus kinase 1 Mus musculus 142-146 34253584-3 2021 To leverage these unique biologic features, we conducted an integrated human and murine study evaluating ruxolitinib, a JAK1/2 inhibitor that potently downregulates intracellular GM-CSF signaling. ruxolitinib 105-116 Janus kinase 1 Mus musculus 120-126 34274356-0 2021 The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. baricitinib 21-32 Janus kinase 1 Mus musculus 4-10 34172892-1 2021 We assessed the impact of the Janus Kinase (JAK) 1 inhibitor itacitinib on xenogeneic graft-versus-host disease (xGVHD). INCB039110 61-71 Janus kinase 1 Mus musculus 30-50 34600581-15 2021 More interestingly, shikonin blocked the phosphorylation of Janus kinase 1/signal transducer andactivator of transcription 1/signal transducer andactivator of transcription 6 in synovial tissues and in fibroblast like synoviocytes. shikonin 20-28 Janus kinase 1 Mus musculus 60-74 34274356-4 2021 OBJECTIVE: Here we compared the effects of the JAK1/2 inhibitor baricitinib and the JAK3 inhibitor tofacitinib on eosinophil effector function in vitro and in vivo. baricitinib 64-75 Janus kinase 1 Mus musculus 47-53 34274356-10 2021 CONCLUSION: Our data suggest that the JAK1/2 inhibitor baricitinib is even more potent than the JAK3 inhibitor tofacitinib in suppressing eosinophil effector function. baricitinib 55-66 Janus kinase 1 Mus musculus 38-44 34558146-7 2021 Furthermore, we analyzed that the molecular mechanical action of lycorine considerably repressed JAK1/STAT3 transactional activation and decrease its downstream molecules Bcl-2, and enhances the expressional activity of Bax, cytochrome c, caspase 3 and 9 in HT-3 cells. lycorine 65-73 Janus kinase 1 Mus musculus 97-101 34335912-12 2021 Signaling studies demonstrated that hispidin markedly suppresses LPS-induced mitogen activated protein kinases and JAK1/STAT3 activation, although not the NF-kappaB signaling pathway. hispidin 36-44 Janus kinase 1 Mus musculus 115-119 34496019-5 2021 These effects were abrogated by the JAK1/JAK2 inhibitor ruxolitinib. ruxolitinib 56-67 Janus kinase 1 Mus musculus 36-40 34232994-2 2021 Experimental and early clinical reports have shown that ruxolitinib, a small molecule inhibitor of Janus kinases (JAKs) which are essential for cytokine signaling, may be therapeutic in HLH. ruxolitinib 56-67 Janus kinase 1 Mus musculus 114-118 34497607-1 2021 Objective: Baricitinib, a selective inhibitor for janus kinase (JAK) 1 and JAK2, is approved for use in rheumatoid arthritis. baricitinib 11-22 Janus kinase 1 Mus musculus 50-70 35411464-0 2022 Astragalin attenuates depression-like behaviors and memory deficits and promotes M2 microglia polarization by regulating IL-4R/JAK1/STAT6 signaling pathway in a murine model of perimenopausal depression. astragalin 0-10 Janus kinase 1 Mus musculus 127-131 34184542-0 2021 Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models. ruxolitinib 0-11 Janus kinase 1 Mus musculus 15-19 34367186-2 2021 Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. ruxolitinib 0-11 Janus kinase 1 Mus musculus 36-43 34367186-2 2021 Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. ruxolitinib 13-16 Janus kinase 1 Mus musculus 36-43 34194525-0 2021 Andrographolide Inhibition of Th17-Regulated Cytokines and JAK1/STAT3 Signaling in OVA-Stimulated Asthma in Mice. andrographolide 0-15 Janus kinase 1 Mus musculus 59-63 35599279-10 2022 In STZ-induced mice, retinal vascular leakage, p-JAK1, p-JAK2, p-JAK3, p-STAT3, and VEGF were significantly increased after diabetes induction. Streptozocin 3-6 Janus kinase 1 Mus musculus 49-53 35599279-12 2022 Increased p-JAK1 and VEGF in STZ-induced mice were significantly reduced by JAKiI (p < 0.05, p < 0.001) and tofacitinib (p < 0.001, respectively). Streptozocin 29-32 Janus kinase 1 Mus musculus 12-16 35599279-12 2022 Increased p-JAK1 and VEGF in STZ-induced mice were significantly reduced by JAKiI (p < 0.05, p < 0.001) and tofacitinib (p < 0.001, respectively). tofacitinib 108-119 Janus kinase 1 Mus musculus 12-16 34356895-8 2021 Blocking JAK1 with Tofacitinib prevented IL-17A-mediated claudin-5 dysmorphia in bEnd.3 cells and reduced albumin leakage in IL-17A-treated mice. tofacitinib 19-30 Janus kinase 1 Mus musculus 9-13 34196308-5 2021 Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1. ruxolitinib 69-80 Janus kinase 1 Mus musculus 49-53 34196308-5 2021 Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1. mv-s-nap-upa 207-219 Janus kinase 1 Mus musculus 49-53 34498493-0 2021 Nitric Oxide Induces a Janus Kinase-1-Dependent Inflammatory Response in Primary Murine Astrocytes. Nitric Oxide 0-12 Janus kinase 1 Mus musculus 23-37 34515136-0 2021 Jak1/Stat3 Activation Alters Phosphate Metabolism Independently of Sex and Extracellular Phosphate Levels. Phosphates 29-38 Janus kinase 1 Mus musculus 0-4 34515136-0 2021 Jak1/Stat3 Activation Alters Phosphate Metabolism Independently of Sex and Extracellular Phosphate Levels. Phosphates 89-98 Janus kinase 1 Mus musculus 0-4 34515136-2 2021 Previously, we showed that activation of the Janus kinase 1 (Jak1)-signal transducer and activator of transcription 3 (Stat3) signaling pathway leads to altered mineral metabolism with higher FGF23 levels, lower PTH, and higher calcitriol levels. Calcitriol 228-238 Janus kinase 1 Mus musculus 45-59 34515136-2 2021 Previously, we showed that activation of the Janus kinase 1 (Jak1)-signal transducer and activator of transcription 3 (Stat3) signaling pathway leads to altered mineral metabolism with higher FGF23 levels, lower PTH, and higher calcitriol levels. Calcitriol 228-238 Janus kinase 1 Mus musculus 61-65 34515136-3 2021 Here, we investigated if there are sex differences in the role of Jak1/Stat3 signaling pathway on phosphate metabolism and if this pathway is sensitive to extracellular phosphate alterations. Phosphates 169-178 Janus kinase 1 Mus musculus 66-70 34515136-5 2021 Furthermore, we challenged Jak1S645P+/- male and female mice with a high (1.2% w/w) and low (0.1% w/w) phosphate diet and a diet with phosphate with organic origin with lower bioavailability. Phosphates 134-143 Janus kinase 1 Mus musculus 27-31 35606820-5 2022 The goal of this study is to determine if the JAK1/JAK2 inhibitor baricitinib impairs type 1 diabetes autoimmunity and preserves beta cell function. baricitinib 66-77 Janus kinase 1 Mus musculus 46-50 35589917-1 2022 Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). ruxolitinib 71-82 Janus kinase 1 Mus musculus 47-53 35241815-4 2022 By using syngeneic mouse models of colorectal cancer, we show that random forest classifiers trained on mass spectrometry signatures from a library of alphaPD1-conjugated mass-barcoded activity sensors for differentially expressed tumour proteases and immune proteases can be used to detect early antitumour responses and discriminate resistance to ICB therapy driven by loss-of-function mutations in either the B2m or Jak1 genes. indole-2-carboxylic acid 349-352 Janus kinase 1 Mus musculus 419-423 35371026-6 2022 In addition, we found that the key regulatory molecules (Igha, Ighg1, NF-kappaB, Jak1, and Stat1) in the two pathways were activated in inflammation and inhibited by mogroside V. Thus, mogroside V may be the main bioactivity component in S. grosvenorii that exerts lung humidification and cough relief effects. mogroside V 185-196 Janus kinase 1 Mus musculus 81-85 35131871-4 2022 Here we show in Pax5+/- mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigates the risk of B-ALL following exposure to infection; 1 of 29 animals treated with ruxolitinib developed B-ALL versus 8 of 34 untreated mice. ruxolitinib 103-114 Janus kinase 1 Mus musculus 118-124 35151645-7 2022 In vitro studies have shown that arctigenin significantly inhibited the IFN-alpha-induced CD69 and interferon-stimulated gene (ISG) expressions along with the phosphorylation of JAK1 and STAT1 by nearly half in murine B cells via activating PP2A. arctigenin 33-43 Janus kinase 1 Mus musculus 178-182 35382859-2 2022 Here, we aim to determine the effect and underlying mechanism of JAK1/2 inhibition on liver fibrosis and hepatic stellate cells (HSCs) and further explore the therapeutic efficacy of Ruxolitinib, a JAK1/2 selective inhibitor, on preventing and reversing liver fibrosis in mice. ruxolitinib 183-194 Janus kinase 1 Mus musculus 198-204 35371026-5 2022 After a combined analysis of the transcriptome and the proteome, 93 major pathways were screened, and we discovered that mogroside V exerts an anti-inflammation effect in the lung via NF-kappaB and JAK-STAT, both of which are among the signaling pathways mentioned above. mogroside V 121-132 Janus kinase 1 Mus musculus 198-201 35371026-6 2022 In addition, we found that the key regulatory molecules (Igha, Ighg1, NF-kappaB, Jak1, and Stat1) in the two pathways were activated in inflammation and inhibited by mogroside V. Thus, mogroside V may be the main bioactivity component in S. grosvenorii that exerts lung humidification and cough relief effects. mogroside 166-175 Janus kinase 1 Mus musculus 81-85 35040955-6 2022 Additionally, the EPS treatment reduced JAK1, STAT6 and nuclear factor-kappaB (NF-kappaB) expression in the lungs of asthmatic mice. eps 18-21 Janus kinase 1 Mus musculus 40-44 35196494-2 2022 Janus Kinase 1 (JAK1) transduces cytokine-receptor signaling, and JAK inhibitors (Jakinibs), including JAK1-specific filgotinib, break inflammatory cycles in autoimmunity. GLPG0634 117-127 Janus kinase 1 Mus musculus 0-14 35196494-2 2022 Janus Kinase 1 (JAK1) transduces cytokine-receptor signaling, and JAK inhibitors (Jakinibs), including JAK1-specific filgotinib, break inflammatory cycles in autoimmunity. GLPG0634 117-127 Janus kinase 1 Mus musculus 16-20 35196494-2 2022 Janus Kinase 1 (JAK1) transduces cytokine-receptor signaling, and JAK inhibitors (Jakinibs), including JAK1-specific filgotinib, break inflammatory cycles in autoimmunity. GLPG0634 117-127 Janus kinase 1 Mus musculus 103-107 35167829-0 2022 Hexapeptide induces M2 macrophage polarization via the JAK1/STAT6 pathway to promote angiogenesis in bone repair. phenylalanyl-glycyl-histidyl-statyl-alanyl-phenylalanine methyl ester 0-11 Janus kinase 1 Mus musculus 55-59 34940780-8 2022 Furthermore, COS inhibited the JAK2/STAT1 pathways on M1 macrophages and the JAK1/STAT6 pathways on M2 macrophages in KCs. oligochitosan 13-16 Janus kinase 1 Mus musculus 77-81 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 Janus kinase 1 Mus musculus 138-142 33781828-2 2021 To evaluate the anti-inflammatory and regulatory T cells effects of JAK1/2 and STAT3 inhibition, we assessed the JAK 1/2 inhibitor ruxolitinib effects on Th17 cell/Tregs balance. ruxolitinib 131-142 Janus kinase 1 Mus musculus 113-120 33990378-5 2021 In contrast, the clinically used JAK1/2 inhibitor baricitinib was equally potent in blocking IFN-alpha/beta- or IFN-lambda-driven responses. baricitinib 50-61 Janus kinase 1 Mus musculus 33-39 35172257-13 2022 CFF-1 in combination with docetaxol (DTX) produced a synergistic effects by sensitizing the inhibitory effect of DTX on JAK1/STAT3 pathway targeting PD-L1 blockade. Docetaxel 26-35 Janus kinase 1 Mus musculus 120-124 35172257-13 2022 CFF-1 in combination with docetaxol (DTX) produced a synergistic effects by sensitizing the inhibitory effect of DTX on JAK1/STAT3 pathway targeting PD-L1 blockade. Docetaxel 37-40 Janus kinase 1 Mus musculus 120-124 35172257-13 2022 CFF-1 in combination with docetaxol (DTX) produced a synergistic effects by sensitizing the inhibitory effect of DTX on JAK1/STAT3 pathway targeting PD-L1 blockade. Docetaxel 113-116 Janus kinase 1 Mus musculus 120-124 34738874-7 2022 Mechanistically, the receptor tyrosine kinase signaling antibody array revealed that Janus kinase-1 (JAK1) was specifically inhibited by AZD3759, but not by osimertinib. AZD3759 137-144 Janus kinase 1 Mus musculus 101-105 35232350-7 2022 JAK inhibitors, notably ruxolitinib, a, JAK1 or 2 blockers, make cell lines and mouse models more susceptible to radiotherapy, biological response modifier therapy, and oncolytic viral treatment. ruxolitinib 24-35 Janus kinase 1 Mus musculus 40-44 34043988-3 2021 In this study, we evaluated the effect of topically applied Baricitinib, JAK1/2 inhibitor on chronic 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced psoriasis model in mice. Tetradecanoylphorbol Acetate 101-137 Janus kinase 1 Mus musculus 73-79 33509955-9 2021 PLA2R1-mediated cell senescence in COPD was largely reversed by treatment with the potent JAK1/2 inhibitor ruxolitinib. ruxolitinib 107-118 Janus kinase 1 Mus musculus 90-96 33927721-3 2021 We used baricitinib, a JAK 1/2 inhibitor, to investigate the therapeutic efficacy of inhibiting the JAK/STAT pathway in EAE mice. baricitinib 8-19 Janus kinase 1 Mus musculus 23-30 32814877-5 2021 Mechanistically, RNF220 interacted with STAT1 and mediated the K63-linked polyubiquitination of STAT1 at residue K110, which promoted the interaction between STAT1 and the kinase JAK1. Fmoc-Cys(tBu)-OH 113-117 Janus kinase 1 Mus musculus 179-183 33343569-0 2020 The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-gamma and Common gamma Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 29-32 Janus kinase 1 Mus musculus 4-8 33343569-5 2020 We used a JAK1-selective inhibitor, ABT 317, to better understand the specific role of JAK1 signaling in autoimmune diabetes. abt 317 36-43 Janus kinase 1 Mus musculus 10-14 32530039-0 2020 JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Dexamethasone 54-67 Janus kinase 1 Mus musculus 0-3 32818511-3 2020 Ruxolitinib, a potent Janus kinase (JAK) 1 and 2 inhibitor, has been reported to significantly block the proliferation-related signaling pathway of JAK2/signal transducers and activators of transcription 3 (STAT3) and harbor a broad spectrum of anti-cancer activities, including proliferation inhibition, apoptosis induction, and anti-inflammation. ruxolitinib 0-11 Janus kinase 1 Mus musculus 22-48 32861662-9 2020 Low dose itacitinib administered via cannula directly into the colon was highly efficacious in TNBS-induced colitis but with minimal systemic drug exposure, suggesting localized JAK1 inhibition is sufficient for disease amelioration. INCB039110 9-19 Janus kinase 1 Mus musculus 178-182 32861662-11 2020 This is the first manuscript describing itacitinib as a potent and selective JAK1 inhibitor with anti-inflammatory activity across multiple preclinical disease models. INCB039110 40-50 Janus kinase 1 Mus musculus 77-81 32009245-8 2020 Further, in vitro curcumin intervention inhibited M1-type polarization via the Janus kinase1/2-signal transducer and activator of transcription protein1 (JAK1/2-STAT1) pathway. Curcumin 18-26 Janus kinase 1 Mus musculus 154-160 32009245-10 2020 Curcumin prevents inflammatory-mediated apoptosis of osteocytes in part through inhibition of M1 polarization through the JAK1/2-STAT1 pathway. Curcumin 0-8 Janus kinase 1 Mus musculus 122-126 32530039-5 2020 Notably, many cytokines that are elevated in HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in murine HLH models and humans with refractory disease. ruxolitinib 105-116 Janus kinase 1 Mus musculus 88-94 32530039-5 2020 Notably, many cytokines that are elevated in HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in murine HLH models and humans with refractory disease. ruxolitinib 118-121 Janus kinase 1 Mus musculus 88-94 32530039-6 2020 We recently reported that cytokine-induced JAK/STAT signaling mediates DEX resistance in T cell acute lymphoblastic leukemia (T-ALL) cells, and that this could be effectively reversed by RUX. Dexamethasone 71-74 Janus kinase 1 Mus musculus 43-46 32530039-7 2020 Based on these findings, we hypothesized that cytokine-mediated JAK/STAT signaling might similarly contribute to DEX resistance in HLH and that RUX treatment would overcome this phenomenon. Dexamethasone 113-116 Janus kinase 1 Mus musculus 64-67 32527540-0 2020 Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors. triazolo [1,5-a] pyridine 13-38 Janus kinase 1 Mus musculus 60-66 32527540-2 2020 Aiming to develop potent JAK1/2 inhibitors, two series of triazolo [1,5-a] pyridine derivatives were designed and synthesized by various strategies. triazolo [1,5-a] pyridine 58-83 Janus kinase 1 Mus musculus 25-31 32411769-1 2020 Background: Ruxolitinib is an inhibitor of Janus kinases (JAK) 1/2. ruxolitinib 12-23 Janus kinase 1 Mus musculus 43-66 32572733-9 2020 Curcumin was found to block mRNA expressions of non- SMAD genes EGFR, JNK-1, JAK1, JAK2, STAT-1, STAT-3, MAPK14, also of TGF-beta1 and SMAD genes like SMAD 2, SMAD 3. Curcumin 0-8 Janus kinase 1 Mus musculus 77-81 32064962-0 2020 Lysergic acid diethylamide causes mouse retinal damage by up-regulating p-JAK1/p-STAT1. Lysergic Acid Diethylamide 0-26 Janus kinase 1 Mus musculus 74-78 32676080-11 2020 (v) Ruxolitinib, a selective JAK-1/2 inhibitor, attenuated SAg-induced T cell activation, cytokine production, and small bowel pathology, thereby completely protecting from lethal CRS in both WT and IL-17A deficient HLA-DR3 mice. ruxolitinib 4-15 Janus kinase 1 Mus musculus 29-36 32548076-5 2020 Oclacitinib is known to inhibit JAK1 and JAK2 cell signaling pathways, which should limit the antiviral Type I interferon response. oclacitinib 0-11 Janus kinase 1 Mus musculus 32-36 32397290-11 2020 In addition, BHT significantly inhibited the phosphorylation of JAK1 and STAT6 expressions. Butylated Hydroxytoluene 13-16 Janus kinase 1 Mus musculus 64-68 32397290-13 2020 In conclusion, BHT mitigated airway inflammation by down-regulating pro-inflammatory and Th2-related cytokines via JAK1/STAT6 signaling. Butylated Hydroxytoluene 15-18 Janus kinase 1 Mus musculus 115-119 32289835-0 2020 Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study. GLPG0634 67-77 Janus kinase 1 Mus musculus 87-92 32289835-1 2020 Filgotinib is a selective JAK1 (Janus kinase) inhibitor, filed in Japan for the treatment of rheumatoid arthritis. GLPG0634 0-10 Janus kinase 1 Mus musculus 26-30 32495566-0 2020 [Paeonol inhibits macrophage M1 polarization by down-regulating miR-155/JAK1-STAT1 pathway]. paeonol 1-8 Janus kinase 1 Mus musculus 72-76 32495566-7 2020 Paeonol significantly reduced the LPS and IFN-gamma-induced high expression of F4/80 and CD86, the secretion of inflammatory factors IL-6 and TNF-alpha(P<0.05 or P<0.01), decreased the expression level of miR-155, significantly down-regulated the protein phosphorylation level of JAK1-STAT1 and up-regulated the protein expression of SOCS1(P<0.01) in RAW264.7 cells. paeonol 0-7 Janus kinase 1 Mus musculus 280-284 32495566-8 2020 The results showed that paeonol could inhibit M1 polarization of macrophages by down-regulating cell surface marker factors and inflammatory factors secreted by cells, which may be related to the down-regulation of miR-155 expression and the inhibition JAK1-STAT1 pathway activation. paeonol 24-31 Janus kinase 1 Mus musculus 253-257 32004989-8 2020 Moreover, convallatoxin reduced the P-STAT3 (T705) via the JAK1, JAK2, and Src pathways and inhibited serine-727 phosphorylation of STAT3 via the PI3K-AKT-mTOR-STAT3 pathways in colorectal cancer cells. convallatoxin 10-23 Janus kinase 1 Mus musculus 59-63 31811869-0 2020 Inhibition of tyrosine kinase signaling by tyrphostin AG126 downregulates the IL-21/IL-21R and JAK/STAT pathway in the BTBR mouse model of autism. Tyrphostins 43-53 Janus kinase 1 Mus musculus 95-98 31811869-0 2020 Inhibition of tyrosine kinase signaling by tyrphostin AG126 downregulates the IL-21/IL-21R and JAK/STAT pathway in the BTBR mouse model of autism. AG 127 54-59 Janus kinase 1 Mus musculus 95-98 31811869-8 2020 Our results further demonstrated that AG126 treatment effectively decreased IL-21, IL-22, IL-1beta, TNF-alpha, NOS2, JAK1, and STAT3, and increased IL-27 and Foxp3 mRNA and protein expression in brain tissues. AG 127 38-43 Janus kinase 1 Mus musculus 117-121 31811869-9 2020 Our findings suggest that AG126 elicits a neuroprotective response through downregulation of the IL-21/IL-21R and JAK/STAT pathway in BTBR mice, which could represent a promising novel therapeutic target for ASD treatment. AG 127 26-31 Janus kinase 1 Mus musculus 114-117 31556112-0 2020 PRR34-AS1 overexpression promotes protection of propofol pretreatment against ischemia/reperfusion injury in a mouse model after total knee arthroplasty via blockade of the JAK1-dependent JAK-STAT signaling pathway. Propofol 48-56 Janus kinase 1 Mus musculus 173-177 31556112-7 2020 Attenuated symptoms were observed in mice pretreated with propofol, which was evidenced by decreased positive expression rate of JAK1 protein and superoxide dismutase content along with increased malondialdehyde content and IL-10 levels. Propofol 58-66 Janus kinase 1 Mus musculus 129-133 31556112-12 2020 Upregulation of PRR34-AS1 can potentially relieve I/R injury after TKA in mice pretreated with propofol through inhibition of the JAS-STAT signaling pathway by targeting JAK1. Propofol 95-103 Janus kinase 1 Mus musculus 170-174 32345774-0 2020 miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1. mir-140-3p 0-10 Janus kinase 1 Mus musculus 75-89 31812773-11 2020 Finally, verteporfin exhibited an anti-inflammation effect by crosslinking of protein such as NF-kappaB p65, JAK1, JAK2, STAT1, or STAT3 leading to inflammation. verteporfin 9-20 Janus kinase 1 Mus musculus 109-113 31929748-1 2020 Ruxolitinib is a selective inhibitor of Jak1/2. ruxolitinib 0-11 Janus kinase 1 Mus musculus 40-46 31749302-4 2020 Unfortunately, ruxolitinib, the JAK1/2 inhibitor approved by FDA and EMEA for PMF, ameliorates symptoms but does not improve the natural course of the disease, and the cure of PMF is still an unmet clinical need. ruxolitinib 15-26 Janus kinase 1 Mus musculus 32-38 31749302-4 2020 Unfortunately, ruxolitinib, the JAK1/2 inhibitor approved by FDA and EMEA for PMF, ameliorates symptoms but does not improve the natural course of the disease, and the cure of PMF is still an unmet clinical need. emea 69-73 Janus kinase 1 Mus musculus 32-38 33521321-5 2020 JAK inhibitors, particularly the JAK1/2 inhibitor ruxolitinib, sensitize cell lines and murine models to chemotherapy, immunotherapy, and oncolytic viral therapy. ruxolitinib 50-61 Janus kinase 1 Mus musculus 33-39 32345774-9 2020 Besides, JAK1 was proved as a target of miR-140-3p and its restoration reversed miR-140-3p-mediated regulatory effect on progression of NSCLC. mir-140-3p 40-50 Janus kinase 1 Mus musculus 9-13 32345774-9 2020 Besides, JAK1 was proved as a target of miR-140-3p and its restoration reversed miR-140-3p-mediated regulatory effect on progression of NSCLC. mir-140-3p 80-90 Janus kinase 1 Mus musculus 9-13 32345774-10 2020 We concluded that miR-140-3p inhibited NSCLC progression by targeting JAK1, providing a novel avenue for treatment of NSCLC. mir-140-3p 18-28 Janus kinase 1 Mus musculus 70-74 31407334-5 2019 Accordingly, administration of the JAK1/2 selective tyrosine kinase inhibitor ruxolitinib reduced proliferation of tumor cells and effectively reduced tumor progression in immunodeficient and immunocompetent mouse models of K-RAS-driven lung AC. ruxolitinib 78-89 Janus kinase 1 Mus musculus 35-41 31543322-5 2019 Janus kinase 1 inhibitor GLPG0634 or placebo was administered orally before intestinal manipulation. GLPG0634 25-33 Janus kinase 1 Mus musculus 0-14 31586906-12 2019 Furthermore, GAAS decreased hepatocyte apoptosis by blocking the JAK1/STAT1/IRF1 pathway, suppressing oxidative stress, decreasing p-JNK expression, and regulating the expression of apoptosis-related proteins. Glycyrrhizic Acid 13-17 Janus kinase 1 Mus musculus 65-69 31634789-8 2019 Thus, these results suggest that CS12192 as a novel selective JAK inhibitor has therapeutic potential for the treatment of RA and may provide a new strategy for the control of autoimmune diseases. cs12192 33-40 Janus kinase 1 Mus musculus 62-65 31637674-2 2019 Currently, only allogeneic stem cell transplantation is curative in those who are candidates, while administration of the JAK1/2 inhibitor ruxolitinib carries a risk of worsening cytopenia. ruxolitinib 139-150 Janus kinase 1 Mus musculus 122-128 31647203-12 2019 The expression of Jak1 and Jak3 mRNA and pSTAT3, MMP2 and MMP9 proteins in the anti-IL-9 group was lower than that of the PBS or IgG groups (p < 0.05), but the STAT3 and VEGF protein levels showed no significant difference (p < 0.05). pbs 122-125 Janus kinase 1 Mus musculus 18-22 31386778-0 2019 ALA-PDT alleviates the psoriasis by inhibiting JAK signalling pathway. 5-amino levulinic acid 0-3 Janus kinase 1 Mus musculus 47-50 31386778-8 2019 RESULTS: The result showed that ALA-PDT"s anti-proliferation effect and regulation on Socs1/3, JAK1/2 and K17 in IFN-gamma-induced keratinocytes were largely weakened by NAC, indicating that ALA-PDT attenuated the proliferation of IFN-gamma-induced keratinocytes by enhancing ROS level. 5-amino levulinic acid 32-35 Janus kinase 1 Mus musculus 95-101 31511209-0 2019 [Calenduloside E inhibits lipopolysaccharide-induced inflammatory response by inhibiting activation of ROS-mediated JAK1-stat3 signaling pathway in RAW264.7 cells]. Reactive Oxygen Species 103-106 Janus kinase 1 Mus musculus 116-120 31195136-4 2019 This effect was blocked by ruxolitinib, a JAK1/JAK2 inhibitor. ruxolitinib 27-38 Janus kinase 1 Mus musculus 42-46 31561750-3 2019 Baricitinib is a JAK 1/2 inhibitor approved in the USA, EU, and Japan for rheumatoid arthritis, demonstrating potent inhibition of IL-6, D-dimer, CRP, TNF-alpha, IFN-alpha/beta, and other pro-inflammatory cytokines. baricitinib 0-11 Janus kinase 1 Mus musculus 17-24 31378597-5 2019 Furthermore, cellular morphology observation and western blot analysis disclosed the ability of 11e to relieve cells inflammatory damage by significantly down-regulating LPS-induced high expression of JAK1, JAK2, as well as pro cytokine IL-1beta. N-[(2-Amino-1,3-Benzothiazol-6-Yl)carbonyl]glycine 96-99 Janus kinase 1 Mus musculus 201-205 28834694-8 2019 Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, was then utilized as a novel salvage therapy based on available in vivo murine data at the time. ruxolitinib 0-11 Janus kinase 1 Mus musculus 15-37 31511209-0 2019 [Calenduloside E inhibits lipopolysaccharide-induced inflammatory response by inhibiting activation of ROS-mediated JAK1-stat3 signaling pathway in RAW264.7 cells]. calenduloside E 1-16 Janus kinase 1 Mus musculus 116-120 31511209-7 2019 Calenduloside E dose-dependently decreased the expression levels of iNOS and COX-2 induced by LPS, inhibited LPS-induced release of TNF-alpha and IL-1beta, and suppressed LPS-induced JAK1-stat3 signaling pathway activation and stat3 nuclear translocation. calenduloside 0-13 Janus kinase 1 Mus musculus 183-187 31511209-9 2019 CONCLUSIONS: Calenduloside E inhibits LPS-induced inflammatory response by blocking ROS-mediated activation of JAK1-stat3 signaling pathway in RAW264.7 cells. calenduloside E 13-28 Janus kinase 1 Mus musculus 111-115 31511209-9 2019 CONCLUSIONS: Calenduloside E inhibits LPS-induced inflammatory response by blocking ROS-mediated activation of JAK1-stat3 signaling pathway in RAW264.7 cells. Reactive Oxygen Species 84-87 Janus kinase 1 Mus musculus 111-115 31497193-0 2019 Dimethyl fumarate suppresses hepatocellular carcinoma progression via activating SOCS3/JAK1/STAT3 signaling pathway. Dimethyl Fumarate 0-17 Janus kinase 1 Mus musculus 87-91 31497193-8 2019 Treatment with DMF activated SOCS3, which led to repression of JAK1 and STAT3 phosphorylation. Dimethyl Fumarate 15-18 Janus kinase 1 Mus musculus 63-67 31497193-9 2019 DMF inhibited cell proliferation, angiogenesis, and autophagy via activation of the SOCS3/JAK1/STAT3 signaling pathway. Dimethyl Fumarate 0-3 Janus kinase 1 Mus musculus 90-94 31182999-8 2019 We conclude that MRS has a protective effect on acetic acid-induced ulcerative colitis in mice via blocking the TLR4/NF-kappaB/MAPK signaling pathway and promoting the IL-10/JAK1/STAT3-mediated anti-inflammatory response. Acetic Acid 48-59 Janus kinase 1 Mus musculus 174-178 31182999-0 2019 Protective Effect of Methane-Rich Saline on Acetic Acid-Induced Ulcerative Colitis via Blocking the TLR4/NF-kappaB/MAPK Pathway and Promoting IL-10/JAK1/STAT3-Mediated Anti-inflammatory Response. Sodium Chloride 34-40 Janus kinase 1 Mus musculus 148-152 31078568-8 2019 SRI110 co-treatment reversed the cisplatin-induced changes in the expression levels of Bcl2l1, Ccnd1, Jak2, Jak3, and Src and significantly attenuated the changes in the expression levels of Cdkn1a, Egfr, Fas, Il6st, Jak1, Stat3, and Tyk2. sri110 0-6 Janus kinase 1 Mus musculus 217-221 31078568-8 2019 SRI110 co-treatment reversed the cisplatin-induced changes in the expression levels of Bcl2l1, Ccnd1, Jak2, Jak3, and Src and significantly attenuated the changes in the expression levels of Cdkn1a, Egfr, Fas, Il6st, Jak1, Stat3, and Tyk2. Cisplatin 33-42 Janus kinase 1 Mus musculus 217-221 31257541-6 2019 The present study suggested that sulforaphane exerted a therapeutic effect in the AD mouse model through the activation of the Nrf2/HO-1 axis as well as the suppression of Janus kinase 1/STAT3 signaling pathway. sulforaphane 33-45 Janus kinase 1 Mus musculus 172-186 30521964-13 2019 Furthermore, overexpression of THRIL enhanced the LPS-induced JAK1/STAT3 and NF-kappaB pathways activation by down-regulating miR-125b. thril 31-36 Janus kinase 1 Mus musculus 62-66 30899259-11 2019 As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells. Tyrosine 12-20 Janus kinase 1 Mus musculus 39-45 30899259-11 2019 As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells. Tyrosine 12-20 Janus kinase 1 Mus musculus 114-120 30899259-11 2019 As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells. ruxolitinib 147-158 Janus kinase 1 Mus musculus 39-45 30899259-11 2019 As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells. ruxolitinib 147-158 Janus kinase 1 Mus musculus 114-120 30899259-11 2019 As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells. Tyrosine 46-54 Janus kinase 1 Mus musculus 39-45 30899259-11 2019 As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells. Tyrosine 46-54 Janus kinase 1 Mus musculus 114-120 30668755-11 2019 CONCLUSION: JAK1i and tofacitinib but not JAK3i induce phenotypical and functional characteristics of anti-inflammatory macrophages, suggesting JAK1 as the main effector pathway for tofacitinib in these cells. tofacitinib 182-193 Janus kinase 1 Mus musculus 12-16 30635766-2 2019 The anti-MM effects of the selective JAK1 inhibitor INCB052793 (INCB) alone and in combination with anti-MM agents were evaluated in vitro and in vivo. incb052793 52-62 Janus kinase 1 Mus musculus 37-41 30521964-15 2019 Overexpression of THRIL promoted LPS-induced ATDC5 cell inflammatory injury by down-regulating miR-125b and then activating JAK1/STAT3 and NF-kappaB pathways. thril 18-23 Janus kinase 1 Mus musculus 124-128 30562763-11 2018 Moreover, baicalin treatment induced cells apoptosis in synovial fluid monocytes and markedly down regulated JAK1/STAT3 but not mitogen-activated protein kinases (MAPKs) expressions in synovium of arthritis. baicalin 10-18 Janus kinase 1 Mus musculus 109-113 30562763-15 2018 Moreover, the molecular mechanism implies suppressed JAK1/STAT3 signaling with baicalin treatment. baicalin 79-87 Janus kinase 1 Mus musculus 53-57 30544712-0 2018 Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 43-54 Janus kinase 1 Mus musculus 23-27 30537988-9 2018 SAHA pretreatment or HDAC knockdown resulted in impaired IFN-gamma signaling, demonstrated by the reduction of JAK2, p-JAK1, p-JAK2, and p-STAT1 expression and inefficient STAT1 nuclear translocation. Vorinostat 0-4 Janus kinase 1 Mus musculus 119-123 30544712-0 2018 Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice. Dinitrochlorobenzene 107-111 Janus kinase 1 Mus musculus 23-27 30544712-2 2018 Momelotinib (MMB) is a novel JAK1/JAK2 inhibitor suppressing the signal transduction of multiple pro-inflammatory cytokines. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 0-11 Janus kinase 1 Mus musculus 29-33 30544712-2 2018 Momelotinib (MMB) is a novel JAK1/JAK2 inhibitor suppressing the signal transduction of multiple pro-inflammatory cytokines. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 13-16 Janus kinase 1 Mus musculus 29-33 30137697-0 2018 Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice. tetrahydrocurcumin 0-18 Janus kinase 1 Mus musculus 152-156 30137697-0 2018 Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice. Curcumin 10-18 Janus kinase 1 Mus musculus 152-156 30137697-8 2018 RESULTS: Both THC and Cur had beneficial effects on asthmatic mice with regard to nasal symptoms, pathological changes (eosinophils and mucus hyper-production), oxidative stress (malondialdehyde), cytokine production (IL-13), Th17 and cytotoxic T cell subsets, and Th2 signalling pathway (IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 axis) activity. tetrahydrocurcumin 14-17 Janus kinase 1 Mus musculus 300-304 30137697-9 2018 THC was more effective than Cur in suppressing tissue eosinophilia, mucus production, and IL-4Ralpha/Jak1/STAT6 pathway activity. tetrahydrocurcumin 0-3 Janus kinase 1 Mus musculus 101-105 30066904-9 2018 Mechanistically, aloin suppressed LPS-induced JAK1-STAT1/3 activation and STAT1/3 nuclear translocation. alloin 17-22 Janus kinase 1 Mus musculus 46-50 30247637-13 2018 Forty-eight hour inhibition of JAK1 with Ruxolitinib of PND2 ovaries in vitro demonstrated concomitant acceleration of primordial follicle activation and apoptosis (P <= 0.001) and upregulation of downstream JAK-STAT pathway members STAT3 and suppressors of cytokine signalling 4 (SOCS4). ruxolitinib 41-52 Janus kinase 1 Mus musculus 31-35 30066904-0 2018 Aloin suppresses lipopolysaccharide-induced inflammation by inhibiting JAK1-STAT1/3 activation and ROS production in RAW264.7 cells. alloin 0-5 Janus kinase 1 Mus musculus 71-75 30066904-11 2018 Collectively, these data suggest that aloin attenuated LPS-induced inflammation by inhibiting ROS-mediated activation of the JAK1-STAT1/3 signalling pathway, thereby inhibiting the nuclear translocation of STAT1/3 in RAW264.7 cells. alloin 38-43 Janus kinase 1 Mus musculus 125-129 30066904-11 2018 Collectively, these data suggest that aloin attenuated LPS-induced inflammation by inhibiting ROS-mediated activation of the JAK1-STAT1/3 signalling pathway, thereby inhibiting the nuclear translocation of STAT1/3 in RAW264.7 cells. Reactive Oxygen Species 94-97 Janus kinase 1 Mus musculus 125-129 30075176-5 2018 Our aim was to determine whether O-GlcNAc promotes the inhibition of IL-10-pathway (JAK1/STAT3/IL-10), inactivationg its action in the vasculature. o-glcnac 33-41 Janus kinase 1 Mus musculus 84-88 30075176-9 2018 KEY FINDINGS: High levels of O-GlcNAc, induced by Thiamet G incubation, increased vascular expression of JAK1, but decreased expression and activity of STAT3. o-glcnac 29-37 Janus kinase 1 Mus musculus 105-109 30075176-9 2018 KEY FINDINGS: High levels of O-GlcNAc, induced by Thiamet G incubation, increased vascular expression of JAK1, but decreased expression and activity of STAT3. thiamet 50-57 Janus kinase 1 Mus musculus 105-109 29778097-8 2018 Furthermore, we showed that only two-week treatment of mice with ruxolitinib, a JAK1/2 inhibitor, blocked STAT5 activation, restored apoptosis, and prevented early lesion progression. ruxolitinib 65-76 Janus kinase 1 Mus musculus 80-86 30172259-0 2018 Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway. Heparin 27-34 Janus kinase 1 Mus musculus 135-149 30172259-11 2018 These protective effects of S-NACH may be attributed to modulation of the IL-4/JAK1 signal transduction pathway through an inhibition of STAT6 phosphorylation and a subsequent inhibition of GATA-3 and inducible NO synthase expression. s-nach 28-34 Janus kinase 1 Mus musculus 79-83 29654783-0 2018 Resveratrol attenuates pro-inflammatory cytokines and activation of JAK1-STAT3 in BTBR T+ Itpr3tf/J autistic mice. Resveratrol 0-11 Janus kinase 1 Mus musculus 68-72 29654783-9 2018 Resveratrol treatment also decreased IL-6, TNF-alpha, IFN-gamma, JAK1, and STAT3 mRNA expression levels as compared with BTBR control mice in the brain tissue. Resveratrol 0-11 Janus kinase 1 Mus musculus 65-69 29654783-11 2018 Taken together, these results indicate the efficacy of resveratrol in reducing cytokines and JAK-1/STAT3 signaling in BTBR mice, which is a novel and important finding and might be important for future therapies in neuroimmune dysfunction. Resveratrol 55-66 Janus kinase 1 Mus musculus 93-98 29345196-10 2018 Hyperactivation of pSTAT3 and inflammation were rescued by AZD1480, a JAK1/2 inhibitor. AZD 1480 59-66 Janus kinase 1 Mus musculus 70-76 29363542-8 2018 In contrast, JAK1/2 inhibitor ruxolitinib significantly ameliorated skin GVHD, protected Lgr5+ HFSCs, and restored hair regeneration and wound healing after SCT. ruxolitinib 30-41 Janus kinase 1 Mus musculus 13-19 29515770-4 2018 Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation. ruxolitinib 0-11 Janus kinase 1 Mus musculus 38-42 29854301-6 2018 In vitro, treating the transformed cell line with the JAK1/2 inhibitor ruxolitinib inhibited ligand-independent signaling and induced cell death. ruxolitinib 71-82 Janus kinase 1 Mus musculus 54-60 29643028-6 2018 The effect of ROS on LPS-induced JAK-STATs signal and the inflammatory response of RAW264.7 cells was detected by ROS scavenger NAC. Reactive Oxygen Species 14-17 Janus kinase 1 Mus musculus 33-36 29034260-5 2017 The HDP-on proliferates without GMCSF and differentiates into the MPhi upon exposure to tamoxifen and ruxolitinib (GMCSF inhibitor via JAK1/2 blockade). Tamoxifen 88-97 Janus kinase 1 Mus musculus 135-141 29100426-5 2017 In addition, PHS-based inhibition of EMT was attributable to the downregulation of the EGFR/JAK1/STAT3 signaling axis, as validated by immunoprecipitation assays and breast tumorigenesis mice models. D-ribo-phytosphingosine 13-16 Janus kinase 1 Mus musculus 92-96 29202476-5 2018 Importantly, treatment of LKB1-defcient mice with the JAK1/2 inhibitor ruxolitinib dramatically decreased polyposis. ruxolitinib 71-82 Janus kinase 1 Mus musculus 54-60 29034260-5 2017 The HDP-on proliferates without GMCSF and differentiates into the MPhi upon exposure to tamoxifen and ruxolitinib (GMCSF inhibitor via JAK1/2 blockade). ruxolitinib 102-113 Janus kinase 1 Mus musculus 135-141 28496202-6 2017 Treatment of cultured PSC with the Jak1/2 inhibitor ruxolitinib reduced STAT3 phosphorylation, cell proliferation, and expression of alpha-smooth muscle actin (alpha-SMA), a marker of PSC activation. ruxolitinib 52-63 Janus kinase 1 Mus musculus 35-41 28854975-8 2017 Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level. ruxolitinib 60-71 Janus kinase 1 Mus musculus 39-43 29088814-8 2017 Decreasing adenosine inhibitted M2 polarization of RAW264.7 cells through inactivating JAK1/STAT3 signal pathway in fasting condition. Adenosine 11-20 Janus kinase 1 Mus musculus 87-91 28539220-0 2017 Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors. Pyrrolopyridazine 36-54 Janus kinase 1 Mus musculus 63-67 28539220-2 2017 Substitution at the C6 position of the pyrrolopyridazine core with aryl groups provided exceptional biochemical potency against JAK1 and JAK3 while maintaining good selectivity against JAK2 and Tyk2. Pyrrolopyridazine 39-56 Janus kinase 1 Mus musculus 128-132 28292965-6 2017 The JAK1/JAK2 inhibitor AZD1480 blocked the effect of cytokines on mouse and human beta-cells by inhibiting MHC class I upregulation. AZD 1480 24-31 Janus kinase 1 Mus musculus 4-8 28645489-11 2017 These results suggest that anti-inflammatory actions of BU may be attributable to the synergism of inhibition of JAK1/STAT1-dependent pathways and reduction in iATP level. Bromisovalum 56-58 Janus kinase 1 Mus musculus 113-117 28542400-0 2017 Intracellular Ca2+ homeostasis and JAK1/STAT3 pathway are involved in the protective effect of propofol on BV2 microglia against hypoxia-induced inflammation and apoptosis. Propofol 95-103 Janus kinase 1 Mus musculus 35-39 28542400-10 2017 More importantly, these effects could be modulated by 25mumol/L propofol via maintaining intracellular Ca2+ homeostasis and via up-regulating the phosphorylation of JAK1 and STAT3 at Tyr705. Propofol 64-72 Janus kinase 1 Mus musculus 165-169 28708884-0 2017 A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. baricitinib 20-31 Janus kinase 1 Mus musculus 2-8 28708884-5 2017 However, treatment with the Jak1/2 inhibitor, baricitinib, markedly inhibited osteoclastogenesis in the co-culture. baricitinib 46-57 Janus kinase 1 Mus musculus 28-34 28645489-5 2017 The Janus kinase 1 (JAK1) inhibitor filgotinib suppressed the NO release much more weakly than that of BU, although filgotinib almost completely prevented LPS-induced STAT1 phosphorylation. GLPG0634 36-46 Janus kinase 1 Mus musculus 4-18 28645489-5 2017 The Janus kinase 1 (JAK1) inhibitor filgotinib suppressed the NO release much more weakly than that of BU, although filgotinib almost completely prevented LPS-induced STAT1 phosphorylation. GLPG0634 36-46 Janus kinase 1 Mus musculus 20-24 28496202-10 2017 In vivo treatment with the Jak1/2 inhibitor ruxolitinib reduced the severity of experimental CP, suggesting that targeting Jak/STAT signaling may represent a promising therapeutic strategy for CP. ruxolitinib 44-55 Janus kinase 1 Mus musculus 27-33 27847179-0 2017 Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib. oclacitinib 86-97 Janus kinase 1 Mus musculus 71-75 28425456-6 2017 Finally, we demonstrated that a high salt concentration decreased IFNGR1 expression in the basolateral membrane of HK2 cells, leading to decreased phosphorylation of activation sites of Janus kinase 1 (JAK1) and Signal Transducers and Activator of Transcription 1 (STAT1), activators of chemokines. Salts 37-41 Janus kinase 1 Mus musculus 186-200 28425456-6 2017 Finally, we demonstrated that a high salt concentration decreased IFNGR1 expression in the basolateral membrane of HK2 cells, leading to decreased phosphorylation of activation sites of Janus kinase 1 (JAK1) and Signal Transducers and Activator of Transcription 1 (STAT1), activators of chemokines. Salts 37-41 Janus kinase 1 Mus musculus 202-206 28425456-7 2017 JAK inhibitor canceled the effect of a high salt concentration on STAT1 and chemokines, indicating that the JAK1-STAT1 signaling pathway is essential for this mechanism. Salts 44-48 Janus kinase 1 Mus musculus 108-112 27567084-7 2016 IFN-gamma increased signal transducer and activator of transcription-1 (STAT-1) phosphorylation to play its position in regulating melanin pigmentation, and its inhibitory effect could be prevented by Janus Kinase 1 (JAK 1) inhibitor. Melanins 131-138 Janus kinase 1 Mus musculus 201-215 27671227-7 2016 The examination of fibroblasts from conditional knockout embryos and their littermate wildtype controls expressing JAK1 showed that lack of this Janus kinase resulted in an impaired tyrosine phosphorylation and activation of the downstream Signal Transducers and Activators of Transcription (STATs) 1, 3, and 6. Tyrosine 182-190 Janus kinase 1 Mus musculus 115-119 27567084-7 2016 IFN-gamma increased signal transducer and activator of transcription-1 (STAT-1) phosphorylation to play its position in regulating melanin pigmentation, and its inhibitory effect could be prevented by Janus Kinase 1 (JAK 1) inhibitor. Melanins 131-138 Janus kinase 1 Mus musculus 217-222 27222478-3 2016 Recently, several Janus kinase 1/2 (JAK1/2) inhibitors, such as ruxolitinib, have been developed as immunosuppressive agents. ruxolitinib 64-75 Janus kinase 1 Mus musculus 36-42 27546461-4 2016 Proteomic and genomic analyses identified an iron-regulated signaling axis mediated by cyclin-dependent kinase 1 (CDK1), JAK1, and STAT3 in CRC progression. Iron 45-49 Janus kinase 1 Mus musculus 121-125 27222478-10 2016 Our findings demonstrate that clinically relevant doses of the JAK1/2 inhibitor ruxolitinib suppresses the harmful consequences of macrophage overactivation characterizing HLH in 2 murine models. ruxolitinib 80-91 Janus kinase 1 Mus musculus 63-69 26687007-8 2015 Eight weeks-treatment with ruxolitinib, an FDA-approved JAK1/2 inhibitor, reduced circulating activin A, preserved fat mass, reduced lipotoxicity, and increased insulin sensitivity in 22-month-old mice. ruxolitinib 27-38 Janus kinase 1 Mus musculus 56-62 26936678-0 2016 Sip-jeon-dea-bo-tang, a traditional herbal medicine, ameliorates cisplatin-induced anorexia via the activation of JAK1/STAT3-mediated leptin and IL-6 production in the fat tissue of mice. Cisplatin 65-74 Janus kinase 1 Mus musculus 114-118 26825707-5 2016 In both models, treatment with the JAK1/2 inhibitor ruxolitinib significantly lessened the clinical and laboratory manifestations of HLH, including weight loss, organomegaly, anemia, thrombocytopenia, hypercytokinemia, and tissue inflammation. ruxolitinib 52-63 Janus kinase 1 Mus musculus 35-41 27034417-1 2016 In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS). ruxolitinib 118-129 Janus kinase 1 Mus musculus 100-106 26164790-2 2015 We focused on the 2 different JAK inhibitors, tofacitinib (selective for JAK3) and oclacitinib (selective for JAK1 and 2), to clarify the mechanism of anti-inflammatory and anti-itching potency of these drugs. oclacitinib 83-94 Janus kinase 1 Mus musculus 110-120 26446793-6 2015 The same cytokine receptor independence as for JAK3(L857P) was observed for homologous Leu(857) mutations of JAK1 and JAK2 and for JAK3(L875H). Leucine 87-90 Janus kinase 1 Mus musculus 109-113 26446793-10 2015 Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P). ruxolitinib 10-21 Janus kinase 1 Mus musculus 51-55 26365358-4 2015 We show that IL-13 impairs ENaC-dependent sodium transport by activating the JAK1/2-STAT6 signalling pathway. Sodium 42-48 Janus kinase 1 Mus musculus 77-83 25798758-5 2015 Analysis of signaling pathways revealed that Rh3 enhanced the phosphorylation of 5"-adenosine monophosphate-activated protein kinase (AMPK) and inhibited Akt and janus kinase 1 (JAK1)/signal transducer and activator of transcription 1 (STAT1) induced by LPS. rh3 45-48 Janus kinase 1 Mus musculus 178-182 25977345-4 2015 EXPERIMENTAL DESIGN: We examined the effect of JAK1/JAK2 modulation by ruxolitinib in a mouse model of fully MHC mismatched bone marrow transplant comprising in vivo tumor inoculation. ruxolitinib 71-82 Janus kinase 1 Mus musculus 47-51 25977345-5 2015 RESULTS: JAK1/JAK2 inhibition by ruxolitinib improved both overall survival (P = 0.03) and acute GVHD pathologic score at target organs (P <= 0.001) of treated mice. ruxolitinib 33-44 Janus kinase 1 Mus musculus 9-13 25736380-7 2015 In multiplex assays on plasma and human tumor tissue from an OSU-03012/sildenafil treated mouse, we noted a profound reduction in uPA signaling and identified FGF and JAK1/2 as response biomarkers for potentially suppressing the killing response. osu 61-64 Janus kinase 1 Mus musculus 167-173 25736380-7 2015 In multiplex assays on plasma and human tumor tissue from an OSU-03012/sildenafil treated mouse, we noted a profound reduction in uPA signaling and identified FGF and JAK1/2 as response biomarkers for potentially suppressing the killing response. Sildenafil Citrate 71-81 Janus kinase 1 Mus musculus 167-173 24577942-0 2014 Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. AZD 1480 56-63 Janus kinase 1 Mus musculus 29-35 25156366-0 2014 Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. Imiquimod 40-49 Janus kinase 1 Mus musculus 23-27 25149535-1 2014 AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase which inhibits STAT3 phosphorylation and tumor growth. AZD 1480 0-7 Janus kinase 1 Mus musculus 61-67 25825724-4 2015 JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance of this is unclear. Adenosine Triphosphate 37-40 Janus kinase 1 Mus musculus 7-11 25825724-8 2015 Disrupting ATP binding in JH2 also inhibits the hyperactivity of other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in a JAK2 V617F myeloproliferative neoplasm mouse model. Adenosine Triphosphate 11-14 Janus kinase 1 Mus musculus 110-114 25825724-10 2015 Taken together, our results suggest that ATP binding to JH2 serves a structural role in JAKs, which is required for aberrant activity of pathogenic JAK mutants. Adenosine Triphosphate 41-44 Janus kinase 1 Mus musculus 88-92 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 108-118 Janus kinase 1 Mus musculus 53-57 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 108-118 Janus kinase 1 Mus musculus 87-91 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 120-131 Janus kinase 1 Mus musculus 53-57 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 120-131 Janus kinase 1 Mus musculus 87-91 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 351-361 Janus kinase 1 Mus musculus 53-57 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 351-361 Janus kinase 1 Mus musculus 87-91 25289677-6 2014 In addition, prolonged administration of INCB018424 further improves survival after allo-HSCT and is superior to other JAK1/JAK2 inhibitors, such as TG101348 or AZD1480. ruxolitinib 41-51 Janus kinase 1 Mus musculus 119-123 24577942-0 2014 Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. AZD 1480 56-63 Janus kinase 1 Mus musculus 29-33 24577942-8 2014 Most importantly, pharmacologic inhibition of Jak1/2 by AZD1480 suppressed IL-6-induced signaling, migratory prostate cancer cell phenotypes, and metastatic dissemination of prostate cancer in vivo in nude mice. AZD 1480 56-63 Janus kinase 1 Mus musculus 46-50 24398427-4 2014 Here, we investigated whether the small-molecule Jak1/2 inhibitor AZD1480 confers therapeutic benefits in two mouse models of inflammation-associated gastrointestinal cancer, which are strictly dependent of excessive Stat3 activation. AZD 1480 66-73 Janus kinase 1 Mus musculus 49-55 24081659-4 2013 Treatment with the JAK1/2 inhibitor ruxolitinib lowered the white blood count and reduced spleen weight. ruxolitinib 36-47 Janus kinase 1 Mus musculus 19-25 24323580-6 2014 We have used AZD1480, a JAK1/2 inhibitor, to investigate the therapeutic potential of inhibiting the JAK/STAT pathway in models of EAE. AZD 1480 13-20 Janus kinase 1 Mus musculus 24-30 24081976-4 2013 EXPERIMENTAL DESIGN: The combination of the JAK1/2 inhibitor ruxolitinib and panobinostat was investigated using two different mouse models of JAK2(V617F)-driven disease. ruxolitinib 61-72 Janus kinase 1 Mus musculus 44-50 24251790-6 2013 The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 72-79 Janus kinase 1 Mus musculus 14-18 23791841-1 2013 Within the Munich, Germany, N-ethyl-N-nitrosourea mouse mutagenesis program, we isolated a dominant Jak1 mouse model resembling phenotypic characteristics related to autoimmune disease. Ethylnitrosourea 28-49 Janus kinase 1 Mus musculus 100-104 23827160-1 2013 CYT387 is an orally bioavailable, small molecule inhibitor of Janus family of tyrosine kinases (JAK) 1 and 2. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 0-6 Janus kinase 1 Mus musculus 78-108 24251790-3 2013 Out of 15 kinase inhibitors, the ZSTK474 phosphatydylinositol-3"-kinase (PI3K) inhibitor molecule showed strong synergic inhibition by Chou and Talalay analysis with JAK2 and JAK2/JAK1 inhibitors. ZSTK474 33-40 Janus kinase 1 Mus musculus 180-184 24251790-6 2013 The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F. ruxolitinib 56-67 Janus kinase 1 Mus musculus 14-18 23531921-2 2013 AZD1480, a pharmacological JAK1/2 inhibitor, exhibits anti-tumor potency in multiple adult malignancies. AZD 1480 0-7 Janus kinase 1 Mus musculus 27-33 23803415-4 2013 We found that garcinol inhibited constitutively activated STAT3 in HNSCC cells in a time- and dose-dependent manner, which correlated with the suppression of the upstream kinases (c-Src, JAK1, and JAK2) in HNSCC cells. garcinol 14-22 Janus kinase 1 Mus musculus 187-191 23613111-0 2013 Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. nitidine 0-17 Janus kinase 1 Mus musculus 103-107 23703473-0 2013 Aspirin enhances IFN-alpha-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway. Aspirin 0-7 Janus kinase 1 Mus musculus 99-103 23703473-5 2013 Further study revealed that aspirin-prompted phosphorylation of STAT1 was activated through phosphorylation of JAK1. Aspirin 28-35 Janus kinase 1 Mus musculus 111-115 23333931-0 2013 25-Hydroxyvitamin D3 attenuates experimental periodontitis through downregulation of TLR4 and JAK1/STAT3 signaling in diabetic mice. Calcifediol 0-20 Janus kinase 1 Mus musculus 94-98 23668484-2 2013 We used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 3. 2,6-dichloro-4-cyanophenyl 43-69 Janus kinase 1 Mus musculus 172-176 23668484-2 2013 We used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 3. (1r,2r)-2-fluorocyclopropylamide 74-106 Janus kinase 1 Mus musculus 172-176 22355274-0 2012 Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. AZD 1480 51-58 Janus kinase 1 Mus musculus 33-39 22355274-3 2012 AZD1480 is a novel small molecule inhibitor of Jak1/2, which is a key mediator of STAT3 activation. AZD 1480 0-7 Janus kinase 1 Mus musculus 47-53 21833847-4 2011 Western blot analysis indicated that JAK1 is significantly phosphorylated, accompanied by the phosphorylation of STAT1 at Tyr(701) within a similar timeframe. Tyrosine 122-125 Janus kinase 1 Mus musculus 37-41 21604762-2 2011 Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. 4-aryl-2-aminopyrimidine 75-99 Janus kinase 1 Mus musculus 156-159 21793847-3 2011 Myricetin strongly inhibited tumor promoter-induced neoplastic cell transformation by inhibiting MEK, JAK1, Akt, and MKK4 kinase activity directly. myricetin 0-9 Janus kinase 1 Mus musculus 102-106 20385788-2 2010 We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional targets. 2-aminopyrimidine 22-37 Janus kinase 1 Mus musculus 74-78 22829185-2 2011 Our novel JAK2 inhibitor, NS-018, was highly active against JAK2 with a 50% inhibition (IC(50)) of <1 n, and had 30-50-fold greater selectivity for JAK2 over other JAK-family kinases, such as JAK1, JAK3 and tyrosine kinase 2. NS-018 26-32 Janus kinase 1 Mus musculus 195-199 20711698-5 2011 T3 decreased tyrosine phosphorylation of JAK1, JAK2 and STAT3, and subsequently inhibited STAT3-DNA binding activity. Tyrosine 13-21 Janus kinase 1 Mus musculus 41-45 21138870-0 2010 Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Curcumin 8-16 Janus kinase 1 Mus musculus 90-96 21138870-6 2010 RESULTS: In vitro, curcumin inhibited JAK1,2/STAT3 tyrosine-phosphorylation in a dose-dependent fashion in murine glioma cell lines. Curcumin 19-27 Janus kinase 1 Mus musculus 38-44 21138870-6 2010 RESULTS: In vitro, curcumin inhibited JAK1,2/STAT3 tyrosine-phosphorylation in a dose-dependent fashion in murine glioma cell lines. Tyrosine 51-59 Janus kinase 1 Mus musculus 38-44 22066025-3 2011 PL was found to selectively inhibit IFN-gamma and IL-17 production by CD4(+) T cells, which was mediated through abrogated phosphorylation of JAK1 and JAK2. plumbagin 0-2 Janus kinase 1 Mus musculus 142-146 20385788-2 2010 We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional targets. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 50-56 Janus kinase 1 Mus musculus 74-78 20060843-8 2010 Biochemical studies revealed that the anti-inflammatory effect of quercetin was accompanied by the down-regulation of extracellular signal-regulated kinase, c-Jun N-terminal kinase, p38, Akt, Src, Janus kinase-1, Tyk2, signal transducer and activator of transcription-1, and NF-kappaB. Quercetin 66-75 Janus kinase 1 Mus musculus 197-211 17803855-1 2007 OBJECTIVE: To investigate the effects of budesonide (BUD) on the airway remodeling and the expression of Janus protein tyrosine kinases 1 (JAK1) and signal transducer and activator of transcription 6 (STAT6) in asthma. Budesonide 41-51 Janus kinase 1 Mus musculus 139-143 18995957-10 2009 Thus, our data indicate that myricetin might directly target JAK1 to block cell transformation in mouse JB6 cells. myricetin 29-38 Janus kinase 1 Mus musculus 61-65 17928529-3 2008 RANKL induced Jak1 ubiquitination, and a proteasome inhibitor MG132 efficiently blocked the RANKL-induced degradation of Jak1. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 62-67 Janus kinase 1 Mus musculus 14-18 17928529-3 2008 RANKL induced Jak1 ubiquitination, and a proteasome inhibitor MG132 efficiently blocked the RANKL-induced degradation of Jak1. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 62-67 Janus kinase 1 Mus musculus 121-125 19561401-9 2009 Secretion of IL6 and levels of JAK1, IL6R and phosphorylated STAT3 were all reduced by triptolide treatment. triptolide 87-97 Janus kinase 1 Mus musculus 31-35 19181385-9 2009 GANP down-regulates JAK1/JAK3 to STAT6-signaling with regulation of arginine methylation activity, which might be responsible for the B cell endogenous suppressive mechanism of hyper-IgE. Arginine 68-76 Janus kinase 1 Mus musculus 20-24 18718058-0 2008 [Regulatory effect of resveratrol on JAK1/STAT3 signal transduction pathway in leukemia]. Resveratrol 22-33 Janus kinase 1 Mus musculus 37-41 18718058-4 2008 The results indicated that resveratrol could significantly inhibit the JAK1/STAT3 signal transduction pathway, down-regulate expressions of pJAK1 and pSTAT3 and reduce the phosphorylation of JAK1 and STAT3 in a dose-and time-dependent manner. Resveratrol 27-38 Janus kinase 1 Mus musculus 71-75 18718058-4 2008 The results indicated that resveratrol could significantly inhibit the JAK1/STAT3 signal transduction pathway, down-regulate expressions of pJAK1 and pSTAT3 and reduce the phosphorylation of JAK1 and STAT3 in a dose-and time-dependent manner. Resveratrol 27-38 Janus kinase 1 Mus musculus 141-145 18718058-5 2008 It is concluded that the resveratrol can regulate signal transduction pathway and reduce the activation of JAK1/STAT3 tyrosine phosphorylation significantly, and therefore resveratrol shows chemotherapeutic potential to leukaemia. Resveratrol 25-36 Janus kinase 1 Mus musculus 107-111 18718058-5 2008 It is concluded that the resveratrol can regulate signal transduction pathway and reduce the activation of JAK1/STAT3 tyrosine phosphorylation significantly, and therefore resveratrol shows chemotherapeutic potential to leukaemia. Tyrosine 118-126 Janus kinase 1 Mus musculus 107-111 18362173-6 2008 Three mutations that were studied promoted JAK1 gain of function and conferred interleukin (IL)-3-independent growth in Ba/F3 cells and/or IL-9-independent resistance to dexamethasone-induced apoptosis in T cell lymphoma BW5147 cells. Dexamethasone 170-183 Janus kinase 1 Mus musculus 43-47 17803855-19 2007 The changes of JAK1 and STAT6 expression were correlated significantly with the changes in the airway score of goblet cells, hydroxyproline content, expression level of alpha-SMA, and levels of IL-4 and IL-13 in BALF (all P < 0.05). Hydroxyproline 125-139 Janus kinase 1 Mus musculus 15-19 15988755-3 2005 IL-3 induces tyrosine phosphorylation of both JAK1 and JAK2. Tyrosine 13-21 Janus kinase 1 Mus musculus 46-50 16737695-7 2006 Immunoprecipitation and Western blot analyses showed that LIF induces tyrosine phosphorylation of JAK1, TYK2 and STAT3 in 30 min and treatment with 15d-PGJ2 or ATRA results in a dose-dependent decrease in LIF-induced phosphorylation of JAK1 and STAT3 in D3-ES cells. Tyrosine 70-78 Janus kinase 1 Mus musculus 98-102 16737695-7 2006 Immunoprecipitation and Western blot analyses showed that LIF induces tyrosine phosphorylation of JAK1, TYK2 and STAT3 in 30 min and treatment with 15d-PGJ2 or ATRA results in a dose-dependent decrease in LIF-induced phosphorylation of JAK1 and STAT3 in D3-ES cells. Tyrosine 70-78 Janus kinase 1 Mus musculus 236-240 16737695-7 2006 Immunoprecipitation and Western blot analyses showed that LIF induces tyrosine phosphorylation of JAK1, TYK2 and STAT3 in 30 min and treatment with 15d-PGJ2 or ATRA results in a dose-dependent decrease in LIF-induced phosphorylation of JAK1 and STAT3 in D3-ES cells. 15-deoxy-delta(12,14)-prostaglandin J2 148-156 Janus kinase 1 Mus musculus 98-102 16737695-7 2006 Immunoprecipitation and Western blot analyses showed that LIF induces tyrosine phosphorylation of JAK1, TYK2 and STAT3 in 30 min and treatment with 15d-PGJ2 or ATRA results in a dose-dependent decrease in LIF-induced phosphorylation of JAK1 and STAT3 in D3-ES cells. 15-deoxy-delta(12,14)-prostaglandin J2 148-156 Janus kinase 1 Mus musculus 236-240 16737695-7 2006 Immunoprecipitation and Western blot analyses showed that LIF induces tyrosine phosphorylation of JAK1, TYK2 and STAT3 in 30 min and treatment with 15d-PGJ2 or ATRA results in a dose-dependent decrease in LIF-induced phosphorylation of JAK1 and STAT3 in D3-ES cells. Tretinoin 160-164 Janus kinase 1 Mus musculus 98-102 16914098-6 2006 This binding plays a role in tyrosine phosphorylation events, catalyzed by JAK1 and JAK2 kinases that result in the phosphorylation and binding of STAT1alpha to the cytoplasmic domain of IFNGR1. Tyrosine 29-37 Janus kinase 1 Mus musculus 75-79 16417589-6 2006 Pretreatment with a JAK inhibitor, AG-490, suppressed phosphorylation of JAK1 and STAT3 at 12 h after SCI, reducing recovery of motor functions. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 35-41 Janus kinase 1 Mus musculus 73-77 15671076-11 2005 A short IL-15 stimulation of TEC induced tyrosine phosphorylation of the main IL-15 signalling molecules (Jak-1, Jak-3, STAT-3 and STAT-5). Tyrosine 41-49 Janus kinase 1 Mus musculus 106-111 15659653-5 2005 We found that Isl1 not only forms a complex with Jak1 and Stat3 but also triggers the tyrosine phosphorylation of Jak1 and its kinase activity, thereby elevating the tyrosine phosphorylation, DNA binding activity, and target gene expression of Stat3. Tyrosine 86-94 Janus kinase 1 Mus musculus 114-118 15659653-5 2005 We found that Isl1 not only forms a complex with Jak1 and Stat3 but also triggers the tyrosine phosphorylation of Jak1 and its kinase activity, thereby elevating the tyrosine phosphorylation, DNA binding activity, and target gene expression of Stat3. Tyrosine 166-174 Janus kinase 1 Mus musculus 114-118 16172266-5 2005 Together with our previous findings, the present study implies that STAT-dependent transcription of the genes responsible for ischemic PC is modulated by a dual signaling mechanism that involves both JAK1/2 (Tyr phosphorylation) and PKCepsilon (Ser phosphorylation). Tyrosine 208-211 Janus kinase 1 Mus musculus 200-206 12842705-7 2003 Tyrosine phosphorylation of Jak1 in KTR cells was not prolonged compared to KT-1cells. Tyrosine 0-8 Janus kinase 1 Mus musculus 28-32 15240680-3 2004 In this study, we show that adenosine suppressed IL-2-dependent proliferation of CTLL-2 T cells by inhibiting STAT5a/b tyrosine phosphorylation that is associated with IL-2R signaling without affecting IL-2-induced phosphorylation of Jak1 or Jak3. Adenosine 28-37 Janus kinase 1 Mus musculus 234-238 11187900-0 2000 A transient dephosphorylation of JAK1 and JAK2 characterises the early-phase response of murine erythroleukemia cells to the differentiation inducer hexamethylenebisacetamide. hexamethylene bisacetamide 149-174 Janus kinase 1 Mus musculus 33-37 12738234-7 2003 We conclude that (i) the upregulation of COX-2 protein expression after ischemic PC is mediated by a JAK1/2-STAT1/3-signaling cascade; (ii) COX-2 activity requires upregulated iNOS and iNOS-derived NO; and (iii) COX-2 forms complexes with iNOS, supporting a direct interaction between these two proteins. pc 81-83 Janus kinase 1 Mus musculus 101-115 12589807-1 2003 The aim of this study was to evaluate the participation of the Jak-1 and STAT-1 proteins in sodium butyrate-induced apoptosis in 2C4 cells derived from human fibrosarcoma. Butyric Acid 92-107 Janus kinase 1 Mus musculus 63-68 12426308-7 2003 In contrast, IL-4-induced tyrosine phosphorylation of Janus kinase-1 and STAT6 is not affected, suggesting that PP2A acts downstream of Janus kinases in IL-4 signaling. Tyrosine 26-34 Janus kinase 1 Mus musculus 54-68 12093291-6 2002 Retroviral-mediated transduction of wild-type gamma c into XSCID JT cells restored function to the IL-21R, as shown by IL-21-induced tyrosine phosphorylation of JAK1 and JAK3, and downstream activation of STAT5, in JT/gamma c cells as well as BaF3/IL-21R alpha and primary splenic B cells. Tyrosine 133-141 Janus kinase 1 Mus musculus 161-165 11866427-6 2002 We also demonstrate that both the Tyk-2 and Jak-1 kinases are required for activation of the CrkL/Rap1 pathway, as the Type I IFN-dependent GTP-bound form of Rap1 is inhibited by overexpression of dominant-negative Tyk-2 or Jak-1 mutants and is defective in cells lacking Tyk-2 or Jak-1. Guanosine Triphosphate 140-143 Janus kinase 1 Mus musculus 44-49 11866427-6 2002 We also demonstrate that both the Tyk-2 and Jak-1 kinases are required for activation of the CrkL/Rap1 pathway, as the Type I IFN-dependent GTP-bound form of Rap1 is inhibited by overexpression of dominant-negative Tyk-2 or Jak-1 mutants and is defective in cells lacking Tyk-2 or Jak-1. Guanosine Triphosphate 140-143 Janus kinase 1 Mus musculus 224-229 11866427-6 2002 We also demonstrate that both the Tyk-2 and Jak-1 kinases are required for activation of the CrkL/Rap1 pathway, as the Type I IFN-dependent GTP-bound form of Rap1 is inhibited by overexpression of dominant-negative Tyk-2 or Jak-1 mutants and is defective in cells lacking Tyk-2 or Jak-1. Guanosine Triphosphate 140-143 Janus kinase 1 Mus musculus 224-229 11481471-7 2001 Pretreatment with the JAK inhibitor AG-490 20 min before the six occlusion/reperfusion cycles blocked the enhanced tyrosine phosphorylation of JAK1 and JAK2 and the increased tyrosine phosphorylation, nuclear translocation, and enhanced DNA-binding activity of STAT1 and STAT3. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 36-42 Janus kinase 1 Mus musculus 143-147 11481471-7 2001 Pretreatment with the JAK inhibitor AG-490 20 min before the six occlusion/reperfusion cycles blocked the enhanced tyrosine phosphorylation of JAK1 and JAK2 and the increased tyrosine phosphorylation, nuclear translocation, and enhanced DNA-binding activity of STAT1 and STAT3. Tyrosine 115-123 Janus kinase 1 Mus musculus 143-147 11278301-6 2001 In contrast, IL-2-induced tyrosine phosphorylation of the kinases Jak1 and Jak3 located upstream of STAT5 was not affected by UV. Tyrosine 26-34 Janus kinase 1 Mus musculus 66-70 11071649-5 2000 Further comparison of upstream signaling pathways revealed that JAK-1 was constitutively present in anti-phosphotyrosine immunoprecipitates of IL-6-independent cells; gp130 was constitutively phosphorylated in a subset of IL-6-independent plasmacytomas, whereas other IL-6-independent lines showed no detectable gp130 phosphorylation in the absence of exogenous IL-6. Phosphotyrosine 105-120 Janus kinase 1 Mus musculus 64-69